By investigating more than a thousand potential targets using several of the largest currently available human genetic datasets, we provide evidence for drug targets of type-I IFNs (IFNAR2) and ACE2 modulators (ACE2) as priority candidates for evaluation in randomized trials of early management in COVID-19. The gene discussed is IFNAR2; the disease is COVID-19.